Iterative Drug Design Using Carbohydrate Scaffolds
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug discovery methods are inefficient due to the need to synthesize a large number of compounds to identify potential active molecules, often resulting in gaps in molecular space scanning and failure to rapidly identify bioactive conformations for therapeutic targets.
Innovation Solution
A method involving iterative scanning libraries, starting with a selected number of pharmacophores in the first library and designing subsequent libraries with additional pharmacophores based on SAR information, using carbohydrate scaffolds to systematically vary pharmacophoric groups and their positions, allowing for rapid identification of active molecules.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a large number of compounds are synthesized to identify potential active molecules, then the reliability of identifying biologically active compounds is improved, but the productivity and time required for drug discovery deteriorates
Solution Approach 1:
The patent applies preliminary action by pre-defining pharmacophoric groups and their spatial arrangements before synthesis. The method uses computational modeling to predict bioactive conformations and designs libraries of compounds with predetermined pharmacophoric groups (e.g., aromatic rings, basic amino acid residues) positioned at specific distances and orientations relative to each other, based on the known or predicted binding site geometry of the therapeutic target. This allows systematic generation of compounds likely to be active without synthesizing every possible molecule.
Solution Approach 2:
The patent applies local quality by focusing the library design on specific critical regions (pharmacophoric groups) that are essential for biological activity, while allowing variability in less critical regions. The method identifies and emphasizes specific spatial relationships between pharmacophoric groups (such as the distance between an aromatic ring and a basic residue) that are crucial for target interaction, while other aspects of the molecule can be varied to optimize properties like solubility or metabolic stability.
2Adaptability or versatility
If random libraries of compounds are generated to scan molecular diversity, then the coverage of molecular space is improved, but the efficiency of identifying bioactive conformations deteriorates
Solution Approach 1:
The patent applies dynamics by creating a flexible, iterative library design process that adapts to biological activity results. The method starts with an initial library based on predicted bioactive conformations, assays these compounds, and then uses the results to refine and redesign subsequent libraries. This dynamic feedback loop allows the molecular diversity scanning to focus on the most promising regions of conformational space identified through previous activity data, rather than randomly sampling the entire space.
Solution Approach 2:
The patent applies segmentation by dividing the molecular structure into distinct pharmacophoric groups (e.g., aromatic rings, basic residues, hydrophobic groups) and systematically varying their combinations and spatial arrangements. Instead of generating random molecules, the method segments the binding site interaction requirements into discrete pharmacophoric elements and creates libraries that systematically combine these segments in different configurations, enabling efficient scanning of conformational space.
3Measurement precision
If the position and orientation of pharmacophoric groups are systematically varied, then the precision of identifying bioactive conformations is improved, but the complexity of library design and synthesis increases
Solution Approach 1:
The patent applies universality by designing a modular library platform that can be adapted to different therapeutic targets and binding sites. The same core approach of systematically varying pharmacophoric group positions and orientations can be applied across different protein targets by simply changing the predicted or known binding site geometry. This universal methodology reduces the need to develop entirely new library design and synthesis protocols for each target, thereby managing complexity while maintaining precision.
Solution Approach 2:
The patent applies parameter changes by systematically varying specific geometric parameters (distances between pharmacophoric groups, angles of orientation, relative positions) to generate diverse conformations. The method focuses on changing a limited set of critical parameters that define bioactive conformations rather than randomly varying all molecular properties. This targeted parameter variation approach maintains precision in identifying bioactive conformations while keeping the library design and synthesis complexity manageable through focused modification rather than exhaustive variation.
Data Source
AI summary
The invention provides a method of identifying biologically active compounds comprising: (a) designing a first library of compounds of formula (1) to scan molecular diversity wherein each compound of the library has at least two pharmacophoric groups R1 to R5 as defined below and wherein compound of the library has same number of pharmacophoric groups; (b) assaying the first library of compounds in one or more biological assay(s); and (c) designing a second library wherein each compound of the second library contains one or more additional pharmacophoric group with respect to the first library; such that the/each component of the first and second library is a compound of formula (1).